Idiopathic pulmonary fibrosis (IPF) is characterized by progressive dyspnea, interstitial infiltrates in lung parenchyma and restriction on pulmonary function testing. IPF is the most common and severe of the idiopathic interstitial pneumonias, with most individuals progressing to respiratory failure. Multipl...
The depletion of B cells results is dramatic improvement in IgG4-RD and there are some data that argue that B cell depletion may benefit patients with SSc as well. Since there is no firm evidence to suggest that autoantibodies contribute to fibrosis in either of these diseases, we posit that...
To assess the role of the endocannabinoid/cannabinoidreceptor 1 (endocannabinoid/CB1R) system in IPF and its interaction with inducible nitric oxide synthase (iNOS) as dual therapeutic targets, we analyzed lungfibrosisand the status of the endocannabinoid/CB1R system and iNOS in mice with bleomycin-...
Idiopathic pulmonary fibrosis is a chronic and usually progressive lung disorder of unknown etiology. A growing body of evidence suggests that, in contrast to other interstitial lung diseases, IPF is a distinct entity in which inflammation is a secondary and non-relevant pathogenic partner. Evidence ...
Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, PF can be grouped into several types. Idiopathic pulmonary fibrosis, or IPF, is the ...
Idiopathic pulmonary fibrosis.(Review)(Disease/Disorder overview)Meltzer, Eric BNoble, Paul W
Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic pulmonary disease that is characterized by the formation of scar tissue within the lungs in the absence of any known provocation. IPF is a rare disease which affects approximately 5 million persons
Pulmonary Disorder Conferences, Pulmonary Disorder Congress, Pulmonary Disorder Symposium, Pulmonary Disorder Events 2020, Pulmonary Disorder Meetings 2020, Pulmonary Disorder Conference 2020, Pulmonary Disorder Workshop 2020, Pulmonary Disorder Conference in Europe Track 10 : Idiopathic Pulmonary Fibrosis Idiopat...
Pulmonary fibrosis is a progressive scarring disorder of the lung with dismal prognosis and no curative therapy. Clusterin, an extracellular chaperone and regulator of cell functions, is reduced in bronchoalveolar lavage fluid of patients with pulmonary fibrosis. However, its distribution and role in ...
Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD)....